Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions
Septic ShockPeritonitis
Interventions
BIOLOGICAL

Arterial blood sampling

All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels

BIOLOGICAL

Ultrafiltrate sampling

All patients will have ultrafiltrate sampling to assess cytokine levels

DEVICE

CVVH using oXiris™ filter

Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter

DEVICE

CVVH using PrismafleX HF1400 filter

Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter

Trial Locations (8)

21033

CHU Francois Mitterrand, Dijon

21079

CHU Dijon - Bocage central, Dijon

33600

Hopital Haut Lévèque - CHU Bordeaux, Pessac

63003

Hopital Universitaire de Clermont Ferrand, Clermont-Ferrand

69003

Anesthesia and Critical Care Medicine Department - Edouard Herriot Hospital, Lyon

69337

Clinique de la Sauvegarde, Lyon

69400

L'Hôpital Nord-Ouest - Villefranche sur Saone, Gleizé

06000

Hôpital Pasteur 2 - Hôpital Universitaire de Nice, Nice

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Hospices Civils de Lyon

OTHER

NCT03426943 - Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™ | Biotech Hunter | Biotech Hunter